Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 3/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 8/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 6/20 | 0.54 |
| ▸ | FLT4 | P35916 | 4/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 5/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515226 | 0.93 | ALK (0.59) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6519864 | 0.92 | ALK (0.60) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6273178 | 0.92 | ALK (0.71) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6277459 | 0.92 | ALK (0.60) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6269370 | 0.91 | ALK (0.58) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6267653 | 0.91 | ALK (0.58) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6266759 | 0.91 | ALK (0.68) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6273919 | 0.90 | ALK (0.58) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL6520348 | 0.90 | ALK (0.58) | ALKAURKAKDRPDGFRBFGFR1 | |
| SCHEMBL146251 | 0.90 | ALK (0.60) | ALKAURKAKDRPDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803829-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-28 | — | — | US | claimed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | claimed |
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | US | claimed |
| EP-2007380-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-31 | — | — | EP | claimed |
| EP-2004180-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-24 | — | — | EP | claimed |
| WO-2007113198-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| WO-2007113212-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | claimed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-8084455-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-27 | — | — | US | disclosed |
| US-7803829-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | disclosed |
| WO-2007113212-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| EP-1580192-A2 | 16-Hydroxyestratrienes as selective estrogens | Schering AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | ABL1, ABL2, LTK | ALK 262/4885AURKA 257/4885KDR 739/4885 |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | ALK 3814/4885AURKA 4579/4885KDR 1077/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | ALK 3814/4885AURKA 4579/4885KDR 1077/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | ALK 327/4885AURKA 273/4885KDR 398/4885 |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | ABL1, LTK, ABL2 | ALK 233/4885AURKA 281/4885KDR 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.